Company News: InDex Pharmaceuticals Appoints Uli Hacksell and Jesper Wiklund to its Board of Directors

InDex Pharmaceuticals today announced that Uli Hacksell and Jesper Wiklund have been appointed as new members of the Board of Directors. Professor Hacksell and Mr Wiklund together bring to InDex over 40 years of senior management experience from the life sciences industry in drug development, commercial operations, and business development.

Uli Hacksell has over 20 years of international management experience from both large pharmaceutical and biotech companies. He was the CEO of ACADIA Pharmaceuticals from September 2000 to March 2015, and led the company from a private start-up to becoming a public multibillion dollar company listed on the NASDAQ. Previously, Prof. Hacksell held senior executive positions at Astra AB and was president of Astra Draco, one of Astra’s largest Research and Development subsidiaries, where he directed an organization of more than 1,100 employees. Earlier in his career he held the position of Professor in Organic Chemistry at Uppsala University. He has a diverse Board experience from several long-term assignments, including SynAct Pharma A/S, SLS Invest AB, Action Pharma A/S and the Swedish Medical Products Agency. He currently serves on the Board of Directors of Uppsala University.

Jesper Wiklund has over 20 years of international commercial experience in the biotechnology and pharmaceutical industry. Mr Wiklund currently holds the position of Managing Director at Oberland Capital. Mr Wiklund was CEO of InDex Pharmaceuticals from September 2011 to March 2015. Over the course of his career he has completed strategic transactions with an aggregate value exceeding USD 700 million. He previously worked at Swedish Orphan Biovitrum where he was responsible for Business Development, at Wyeth Pharmaceuticals and Elan Pharmaceuticals in the United States and at Evotec in Germany. Mr Wiklund has a B.Sc. from St Marys College of California and a MBA from Harvard Business School.